⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACRV News
Acrivon Therapeutics, Inc. Common Stock
Registration Momentum Builds Across the Oncology Pipeline
globenewswire.com
ACRV
KPTI
ERAS
ONCY
INCY
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
prnewswire.com
ACRV
BNTX
IBRX
ONCY
MAIA
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
globenewswire.com
ACRV
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
globenewswire.com
ACRV
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
globenewswire.com
ACRV
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
globenewswire.com
ACRV
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
globenewswire.com
ACRV
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
globenewswire.com
ACRV
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ACRV